Chiltern Acquires Brazil-Based Clinical Research Organization Vigiun
London, UK, April 16, 2009: Chiltern International Limited (Chiltern), a global Clinical Research Organization (CRO) providing clinical development and staffing services in Europe, the Americas and India, today announced the acquisition of Vigiun, a full service Clinical Research Organization located in Sao Paul, Brazil.
Established in 1999 by Eduardo Forleo, MD, and Elisa Halker, BSN, Vigiun has extensive experience conducting clinical trials in a variety of therapeutic areas, in particular infectious disease, oncology, and respiratory.
“We warmly welcome Vigiun to the Chiltern team,” stated John Vann, Executive Vice President, Americas. “The acquisition of Vigiun enhances Chiltern’s growing presence in Latin America, which was established nearly a year ago when we began operations in Argentina under the leadership of Oscar Podestá, our General Manager for Latin America. The knowledge and experience of Eduardo Forleo and Elisa Halker, and all of the Vigiun staff, will further strengthen our ability to serve our clients and continue our strategy for growth in the region.” Dr. Forleo has been appointed Chiltern’s Country Manager for Brazil and Medical Director for Latin America. Ms.Halker will serve as Director of Clinical Operations for Brazil.
Said Dr. Forleo, “This is an exciting time to become a part of Chiltern. Our business has grown to the point that it makes sense to join forces with a global CRO whose mission and values align with ours. I look forward to contributing in very positive ways to the company’s ongoing and future success.”
“I am very pleased to have Vigiun join Chiltern,” said Glenn Kerkhof, Chiltern’s CEO. “Vigiun is an ideal complement to our existing Latin American operations and Chiltern’s presence in 27 other countries as we serve the pharmaceutical and biotech industries globally.”
Latin America has a population of 503 million people, of which 192 million are in Brazil. This vast population provides a significant number of potential patients in all disease areas. Latin America is rich with experienced investigators and is known for high quality data and excellent patient retention in clinical trials.
About Chiltern
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1400 staff across 28 countries. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Further information is available at www.chiltern.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
